Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Avidity Biosciences Inc (NQ: RNA )

40.46 -0.30 (-0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Avidity Biosciences Inc

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
What's Going On With Avidity Biosciences Stock?
Avidity Biosciences Inc (NASDAQ: RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the first-ever successful 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Recap: Avidity Biosciences Q2 Earnings
  Avidity Biosciences (NASDAQ:RNA) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Avidity Biosciences
Avidity Biosciences (NASDAQ:RNA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"
Via Benzinga
AiViva's Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.  
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Nasdaq Turns Higher; Crude Oil Rises Over 2%
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers 
Via Benzinga
US Stocks Turn Lower; Dow Dips 175 Points
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday. 
Via Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
US Stocks Open Higher; Dow Surges 300 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Tuesday. 
Via Benzinga
Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study
The stock has a high IBD Digital rating, but plummeted on the news. 
Via Investor's Business Daily
FDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trial
The FDA has placed a partial clinical hold on new participant enrollment in Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. 
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
Via InvestorPlace
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Monday, 8/29, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 21.7% to $2.3 during Monday's after-market session. The market value of their outstanding shares is at $68.8 million. 
Via Benzinga
Avidity Biosciences Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Avidity Biosciences's (NASDAQ:RNA) reported sales totaled $1.79 million. Despite a 11.17% increase in earnings, the company posted a loss of $34.23... 
Via Benzinga
Avidity Biosciences Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Avidity Biosciences (NASDAQ:RNA) reported Q4 sales of $1.85 million. Earnings fell to a loss of $38.54 million, resulting in a 31.65% decrease from last... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.